CEREZYME
Clinical safety rating: caution
Comprehensive clinical and safety monograph for CEREZYME (CEREZYME).
Imiglucerase is a recombinant form of the lysosomal enzyme β-glucocerebrosidase, which catalyzes the hydrolysis of glucocerebroside to glucose and ceramide. It replaces deficient endogenous enzyme in patients with Gaucher disease, reducing accumulated glucocerebroside in macrophages.
| Metabolism | Metabolized via peptide hydrolysis into small peptides and amino acids; no cytochrome P450 involvement. |
| Excretion | Primarily metabolized via proteolysis into small peptides and amino acids; renal excretion of metabolites is minimal (<5% unchanged). Biliary/fecal excretion not quantified due to protein nature. |
| Half-life | Terminal elimination half-life is approximately 3.6–10.4 hours (median 5.8 hours) after IV infusion. Clinical context: supports weekly or biweekly dosing (30–60 IU/kg every 2 weeks). |
| Protein binding | Not extensively protein-bound; binding to plasma proteins is minimal (<10%). |
| Volume of Distribution | Vd approximately 0.06–0.18 L/kg, approximating plasma volume, indicating limited extravascular distribution. Clinical meaning: enzyme remains largely in circulation and targets macrophages via mannose receptor-mediated uptake. |
| Bioavailability | Administered exclusively intravenously; bioavailability is 100% by the IV route. Not available orally or by other routes. |
| Onset of Action | Intravenous: Reduction in glucocerebroside accumulation observed within weeks to months; subjective improvement in symptoms (e.g., hepatosplenomegaly, bone pain) may begin after 3–6 months of regular dosing. |
| Duration of Action | Sustained enzyme activity persists for 1–2 weeks post-IV infusion, corresponding to dosing interval (every 2 weeks). Clinical effects on organomegaly and hematologic parameters require continuous therapy. |
60 units/kg intravenously every 2 weeks; infusion rate not to exceed 1 mg/min (equivalent to 2 units/kg/min).
| Dosage form | INJECTABLE |
| Renal impairment | No dose adjustment required for renal impairment; drug is renally eliminated but no specific GFR-based guidelines. |
| Liver impairment | No dose adjustment required for hepatic impairment based on Child-Pugh classification; safety in severe hepatic impairment not established. |
| Pediatric use | Weight-based dosing as per adult dose: 60 units/kg intravenously every 2 weeks; same infusion rate restrictions. |
| Geriatric use | No specific geriatric dose adjustments; use with caution due to potential comorbidities and limited geriatric clinical data. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for CEREZYME (CEREZYME).
| Breastfeeding | Breastfeeding safety: Imiglucerase is a large protein (60 kDa) and is likely not excreted into breast milk in significant amounts. M/P ratio: Not known. No reported adverse effects in nursing infants. Caution advised; weigh benefits of breastfeeding vs. risk to infant. |
| Teratogenic Risk | Cerezyme (imiglucerase) is classified as FDA Pregnancy Category C. Animal studies have shown adverse effects (increased resorptions, reduced fetal weight) at doses 2-4 times the human dose, but no well-controlled human studies exist. First trimester exposure: limited data, theoretical risk. Second/third trimester: no known specific fetal risks; placental transfer expected low due to large protein size. |
■ FDA Black Box Warning
No black box warning per FDA labeling.
| Serious Effects |
["Absolute: Known hypersensitivity to imiglucerase or any excipients.","Relative: None specified; use caution in patients with history of severe allergic reactions."]
| Precautions | ["Hypersensitivity reactions including anaphylaxis may occur; premedication with antihistamines and corticosteroids may be required.","Development of IgG or IgE antibodies may reduce efficacy or increase risk of hypersensitivity; monitor antibody titers.","Infusion-related reactions (e.g., flushing, fever, chills) may occur; slow infusion rate or treat symptomatically.","Caution in patients with compromised respiratory function due to possible bronchospasm.","Pulmonary hypertension reported; monitor for signs and symptoms."] |
| Food/Dietary | No known food interactions. No dietary restrictions required. |
Loading safety data…
| Fetal Monitoring | Monitor maternal hemoglobin, platelet count, and visceral organ size (liver, spleen) per standard Gaucher disease management. Fetal monitoring: ultrasound for growth and anatomy if enzyme replacement is initiated during pregnancy. No specific fetal toxicity monitoring required beyond routine prenatal care. |
| Fertility Effects | Imiglucerase does not have known direct effects on fertility. In animal studies, no adverse effects on reproductive performance or fertility were observed at doses up to 2 times the human dose. Gaucher disease itself may cause menstrual irregularities and fertility issues due to systemic involvement; enzyme replacement may improve fertility by controlling disease activity. |
| Clinical Pearls | Imiglucerase is a recombinant form of glucocerebrosidase used in Gaucher disease. Monitor for neutralizing antibodies, particularly in patients with poor response or allergic reactions. Infusion-related reactions may occur; premedicate with antihistamines and corticosteroids if needed. Adjust dose based on disease severity and clinical response, not solely on biomarkers. Avoid use in patients with known hypersensitivity to Chinese hamster ovary cell proteins. |
| Patient Advice | CEREZYME is infused intravenously over 1-2 hours every 2 weeks. · Report any signs of allergic reaction during infusion: hives, difficulty breathing, swelling of face or throat. · Regular monitoring includes blood tests, bone density scans, and abdominal imaging. · Do not stop or skip infusions without consulting your doctor. · Inform healthcare providers about all medications, including over-the-counter drugs and supplements. |